JAHA:中年黑人不同阶段心力衰竭的流行病学特征

2021-04-21 MedSci原创 MedSci原创

在以社区为基础的黑人中,研究人员观察到中年人B阶段HF的发生率很高,这是心血管发病率和死亡率较高的标志。

黑人有较高的心力衰竭(HF)和亚临床左心室重塑的危险因素负担。

近日,血管疾病领域权威杂志JAHA上发表了一篇研究文章,研究人员评估了1871名参加社区动脉粥样硬化风险研究队列的黑人参与者,他们在接受超声心动图检查时接受了常规检查(1993-1996,中位年龄为58岁)。

研究人员估计了4个HF阶段的患病率:(1)0阶段:无危险因素; (2)A阶段:存在HF危险因素(高血压、糖尿病、肥胖、吸烟、血脂异常、无临床心肌梗死的冠状动脉疾病),无心脏结构/功能异常; (3)B阶段:存在既往心肌梗塞、收缩功能障碍、左心室肥大、局部室壁运动异常或左心室扩大; (4)C/D阶段:HF。

研究人员根据HF分期评估了临床HF的发生率,动脉粥样硬化性心血管疾病事件以及随访的全因死亡率。在基线时,0、A、B和C/D阶段HF的患病率分别为3.8%、20.6%、67.0%和8.6%。

随访期间(中位19.0年),309名参与者出现了明显的心力衰竭,390名参与者发生新发心血管疾病,并且651人死亡。HF、心​血管疾病事件和死亡的发生率在0阶段患者中分别为每1000人每年2.4、0.8和7.6人;A阶段患者中分别为7.4、9.7和13.5; B阶段患者中分别为13.6、15.9和22.0。与0/A阶段患者相比,B阶段患者与经调整后的HF、心血管疾病事件和死亡风险增加了1.5至2倍。

由此可见,在以社区为基础的黑人中,研究人员观察到中年人B阶段HF的发生率很高,这是心血管发病率和死亡率较高的标志

原始出处:

Ramachandran S. Vasan.et al.Epidemiology of Heart Failure Stages in Middle‐Aged Black People in the Community: Prevalence and Prognosis in the Atherosclerosis Risk in Communities Study.J AM HEART ASSOC.2021.https://www.ahajournals.org/doi/full/10.1161/JAHA.120.016524

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2033144, encodeId=231f2033144dd, content=<a href='/topic/show?id=cebb653925a' target=_blank style='color:#2F92EE;'>#流行病学特征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65392, encryptionId=cebb653925a, topicName=流行病学特征)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5fca128, createdName=licz0423, createdTime=Wed Jun 23 12:22:34 CST 2021, time=2021-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=961797, encodeId=7985961e97fb, content=厉害, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210504/f96692cb2d2241beb0e61868c6db08f9/90ac90f090144a439fc1bdd72d5ec073.jpg, createdBy=828c1952764, createdName=一剑封情, createdTime=Fri Apr 30 14:28:24 CST 2021, time=2021-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=960012, encodeId=8d56960012a3, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200729/2ee0ca079ce64987b1195eb6aa20a1f4/ae923a98c9704879bacdc81d9fa7479a.jpg, createdBy=a3ab5398909, createdName=ms6000001113694287, createdTime=Sat Apr 24 12:35:55 CST 2021, time=2021-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1268508, encodeId=c9d912685081f, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Fri Apr 23 12:22:34 CST 2021, time=2021-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1411384, encodeId=167c1411384fb, content=<a href='/topic/show?id=91e96538eee' target=_blank style='color:#2F92EE;'>#流行病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65387, encryptionId=91e96538eee, topicName=流行病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=xugumin, createdTime=Fri Apr 23 12:22:34 CST 2021, time=2021-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=959192, encodeId=9fb1959192a9, content=赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66085169796, createdName=146d43f7m73暂无昵称, createdTime=Wed Apr 21 21:55:49 CST 2021, time=2021-04-21, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2033144, encodeId=231f2033144dd, content=<a href='/topic/show?id=cebb653925a' target=_blank style='color:#2F92EE;'>#流行病学特征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65392, encryptionId=cebb653925a, topicName=流行病学特征)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5fca128, createdName=licz0423, createdTime=Wed Jun 23 12:22:34 CST 2021, time=2021-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=961797, encodeId=7985961e97fb, content=厉害, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210504/f96692cb2d2241beb0e61868c6db08f9/90ac90f090144a439fc1bdd72d5ec073.jpg, createdBy=828c1952764, createdName=一剑封情, createdTime=Fri Apr 30 14:28:24 CST 2021, time=2021-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=960012, encodeId=8d56960012a3, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200729/2ee0ca079ce64987b1195eb6aa20a1f4/ae923a98c9704879bacdc81d9fa7479a.jpg, createdBy=a3ab5398909, createdName=ms6000001113694287, createdTime=Sat Apr 24 12:35:55 CST 2021, time=2021-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1268508, encodeId=c9d912685081f, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Fri Apr 23 12:22:34 CST 2021, time=2021-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1411384, encodeId=167c1411384fb, content=<a href='/topic/show?id=91e96538eee' target=_blank style='color:#2F92EE;'>#流行病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65387, encryptionId=91e96538eee, topicName=流行病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=xugumin, createdTime=Fri Apr 23 12:22:34 CST 2021, time=2021-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=959192, encodeId=9fb1959192a9, content=赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66085169796, createdName=146d43f7m73暂无昵称, createdTime=Wed Apr 21 21:55:49 CST 2021, time=2021-04-21, status=1, ipAttribution=)]
    2021-04-30 一剑封情

    厉害

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=2033144, encodeId=231f2033144dd, content=<a href='/topic/show?id=cebb653925a' target=_blank style='color:#2F92EE;'>#流行病学特征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65392, encryptionId=cebb653925a, topicName=流行病学特征)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5fca128, createdName=licz0423, createdTime=Wed Jun 23 12:22:34 CST 2021, time=2021-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=961797, encodeId=7985961e97fb, content=厉害, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210504/f96692cb2d2241beb0e61868c6db08f9/90ac90f090144a439fc1bdd72d5ec073.jpg, createdBy=828c1952764, createdName=一剑封情, createdTime=Fri Apr 30 14:28:24 CST 2021, time=2021-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=960012, encodeId=8d56960012a3, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200729/2ee0ca079ce64987b1195eb6aa20a1f4/ae923a98c9704879bacdc81d9fa7479a.jpg, createdBy=a3ab5398909, createdName=ms6000001113694287, createdTime=Sat Apr 24 12:35:55 CST 2021, time=2021-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1268508, encodeId=c9d912685081f, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Fri Apr 23 12:22:34 CST 2021, time=2021-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1411384, encodeId=167c1411384fb, content=<a href='/topic/show?id=91e96538eee' target=_blank style='color:#2F92EE;'>#流行病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65387, encryptionId=91e96538eee, topicName=流行病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=xugumin, createdTime=Fri Apr 23 12:22:34 CST 2021, time=2021-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=959192, encodeId=9fb1959192a9, content=赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66085169796, createdName=146d43f7m73暂无昵称, createdTime=Wed Apr 21 21:55:49 CST 2021, time=2021-04-21, status=1, ipAttribution=)]
    2021-04-24 ms6000001113694287

    学习了

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=2033144, encodeId=231f2033144dd, content=<a href='/topic/show?id=cebb653925a' target=_blank style='color:#2F92EE;'>#流行病学特征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65392, encryptionId=cebb653925a, topicName=流行病学特征)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5fca128, createdName=licz0423, createdTime=Wed Jun 23 12:22:34 CST 2021, time=2021-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=961797, encodeId=7985961e97fb, content=厉害, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210504/f96692cb2d2241beb0e61868c6db08f9/90ac90f090144a439fc1bdd72d5ec073.jpg, createdBy=828c1952764, createdName=一剑封情, createdTime=Fri Apr 30 14:28:24 CST 2021, time=2021-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=960012, encodeId=8d56960012a3, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200729/2ee0ca079ce64987b1195eb6aa20a1f4/ae923a98c9704879bacdc81d9fa7479a.jpg, createdBy=a3ab5398909, createdName=ms6000001113694287, createdTime=Sat Apr 24 12:35:55 CST 2021, time=2021-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1268508, encodeId=c9d912685081f, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Fri Apr 23 12:22:34 CST 2021, time=2021-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1411384, encodeId=167c1411384fb, content=<a href='/topic/show?id=91e96538eee' target=_blank style='color:#2F92EE;'>#流行病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65387, encryptionId=91e96538eee, topicName=流行病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=xugumin, createdTime=Fri Apr 23 12:22:34 CST 2021, time=2021-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=959192, encodeId=9fb1959192a9, content=赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66085169796, createdName=146d43f7m73暂无昵称, createdTime=Wed Apr 21 21:55:49 CST 2021, time=2021-04-21, status=1, ipAttribution=)]
    2021-04-23 zhaohui6731
  5. [GetPortalCommentsPageByObjectIdResponse(id=2033144, encodeId=231f2033144dd, content=<a href='/topic/show?id=cebb653925a' target=_blank style='color:#2F92EE;'>#流行病学特征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65392, encryptionId=cebb653925a, topicName=流行病学特征)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5fca128, createdName=licz0423, createdTime=Wed Jun 23 12:22:34 CST 2021, time=2021-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=961797, encodeId=7985961e97fb, content=厉害, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210504/f96692cb2d2241beb0e61868c6db08f9/90ac90f090144a439fc1bdd72d5ec073.jpg, createdBy=828c1952764, createdName=一剑封情, createdTime=Fri Apr 30 14:28:24 CST 2021, time=2021-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=960012, encodeId=8d56960012a3, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200729/2ee0ca079ce64987b1195eb6aa20a1f4/ae923a98c9704879bacdc81d9fa7479a.jpg, createdBy=a3ab5398909, createdName=ms6000001113694287, createdTime=Sat Apr 24 12:35:55 CST 2021, time=2021-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1268508, encodeId=c9d912685081f, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Fri Apr 23 12:22:34 CST 2021, time=2021-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1411384, encodeId=167c1411384fb, content=<a href='/topic/show?id=91e96538eee' target=_blank style='color:#2F92EE;'>#流行病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65387, encryptionId=91e96538eee, topicName=流行病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=xugumin, createdTime=Fri Apr 23 12:22:34 CST 2021, time=2021-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=959192, encodeId=9fb1959192a9, content=赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66085169796, createdName=146d43f7m73暂无昵称, createdTime=Wed Apr 21 21:55:49 CST 2021, time=2021-04-21, status=1, ipAttribution=)]
    2021-04-23 xugumin
  6. [GetPortalCommentsPageByObjectIdResponse(id=2033144, encodeId=231f2033144dd, content=<a href='/topic/show?id=cebb653925a' target=_blank style='color:#2F92EE;'>#流行病学特征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65392, encryptionId=cebb653925a, topicName=流行病学特征)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5fca128, createdName=licz0423, createdTime=Wed Jun 23 12:22:34 CST 2021, time=2021-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=961797, encodeId=7985961e97fb, content=厉害, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210504/f96692cb2d2241beb0e61868c6db08f9/90ac90f090144a439fc1bdd72d5ec073.jpg, createdBy=828c1952764, createdName=一剑封情, createdTime=Fri Apr 30 14:28:24 CST 2021, time=2021-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=960012, encodeId=8d56960012a3, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200729/2ee0ca079ce64987b1195eb6aa20a1f4/ae923a98c9704879bacdc81d9fa7479a.jpg, createdBy=a3ab5398909, createdName=ms6000001113694287, createdTime=Sat Apr 24 12:35:55 CST 2021, time=2021-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1268508, encodeId=c9d912685081f, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Fri Apr 23 12:22:34 CST 2021, time=2021-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1411384, encodeId=167c1411384fb, content=<a href='/topic/show?id=91e96538eee' target=_blank style='color:#2F92EE;'>#流行病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65387, encryptionId=91e96538eee, topicName=流行病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=xugumin, createdTime=Fri Apr 23 12:22:34 CST 2021, time=2021-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=959192, encodeId=9fb1959192a9, content=赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66085169796, createdName=146d43f7m73暂无昵称, createdTime=Wed Apr 21 21:55:49 CST 2021, time=2021-04-21, status=1, ipAttribution=)]
    2021-04-21 146d43f7m73暂无昵称

    0

相关资讯

JACC:克隆性造血与左心室射血分数降低的心衰进展风险的相关性

驱动克隆性造血的体细胞突变在LVEF降低的HF患者中很常见,并且与HF加速进展有关

JACC:终末期心衰患者的心肌血管紧张素代谢

衰竭心脏中含有相当多的经典RAS的代谢物,导致HF持续发展

JAHA:心力衰竭患者高密度脂蛋白功能受损

基线时更好的HDL胆固醇外流与随访期间较低的死亡率相关,而与HDL胆固醇无关。心力衰竭患者随访期间HDL胆固醇外流和抗炎能力下降。

Circulation:射频消融治疗合并房颤的心衰患者的获益明显高于单纯药物治疗!

射频消融治疗合并房颤的心衰患者的获益明显高于单纯药物治疗!

BMJ子刊:男子每天4罐能量饮料导致心力衰竭

大量饮用能量饮料可能与心力衰竭有关